Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling
C. Robin Hiley
Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK (E-mail: [email protected] )
Search for more papers by this authorCorresponding Author
William R. Ford
Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK (E-mail: [email protected] )
*Present address: Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF1 3XF, UK. E-mail: [email protected]Search for more papers by this authorC. Robin Hiley
Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK (E-mail: [email protected] )
Search for more papers by this authorCorresponding Author
William R. Ford
Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK (E-mail: [email protected] )
*Present address: Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF1 3XF, UK. E-mail: [email protected]Search for more papers by this authorABSTRACT
Cannabinoids include not only plant-derived compounds (of which Δ9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2-arachidonoylethanolamide) and 2-arachidonoylglycerol. Cannabinoids act on specific, G-protein-coupled, receptors which are currently divided into two types, CB1 and CB2. Relatively selective agonists and antagonists for these receptors have been developed, although one agent (SR141716A) widely used as an antagonist at CB1 receptors has non-cannabinoid receptor-mediated effects at concentrations which are often used to define the presence of the CB1 receptor. Both cannabinoid receptors are primarily coupled to Gi/o proteins and act to inhibit adenylyl cyclase. Stimulation of CB1 receptors also modulates the activity of K+ and Ca2+ channels and of protein kinase pathways including protein kinase B (Akt) which might mediate effects on apoptosis. CB1 receptors may activate the extracellular signal-regulated kinase cascade through ceramide signalling. Cannabinoid actions on the cardiovascular system have been widely interpreted as being mediated by CB1 receptors although there are a growing number of observations, particularly in isolated heart and blood vessel preparations, that suggest that other cannabinoid receptors may exist. Interestingly, the currently identified cannabinoid receptors appear to be related to a wider family of lipid receptor, those for the lysophospholipids, which are also linked to Gi/o protein signalling. Anandamide also activates vanilloid VR1 receptors on sensory nerves and releases the vasoactive peptide, calcitonin gene-related peptide (CGRP), which brings about vasodilatation through its action on CGRP receptors. Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction. Therefore, their cardiovascular effects and the receptors mediating them are the subject of increasing investigative interest.
VI. REFERENCES
- Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L. A., Pertwee, R. G. & Makriyannis, A. (1994). (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. Journal of Medicinal Chemistry. 37, 1889–1893.
- Aikawa, R., Nawano, M., Gu, Y., Katagiri, H., Asano, T., Zhu, W., Nagai, R. & Komuro, I. (2000). Insulin prevents cardio-myocytes from oxidative stress-induced apoptosis through activation of PI3 kinase/Akt. Circulation. 102, 2873–2879.
- Barg, J., Fride, E., Hanus, L., Levy, R., Matus-Leibovitch, N., Heldman, E., Bayewitch, M., Mechoulam, R. & Vogel, Z. (1995). Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. European Journal of Pharmacology. 287, 145–152.
- Bayewitch, M., Avidor-Reiss, T., Levy, R., Barg, J., Mechoulam, R. & Vogel, Z. (1995). The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Letters. 375, 143–147.
- Bayewitch, M., Rhee, M. H., Avidor-Reiss, T., Breuer, A., Mechoulam, R. & Vogel, Z. (1996). (–)-Δ9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. Journal of Biological Chemistry. 271, 9902–9905.
- Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A. & Piomelli, D. (1997). Functional role of high–affinity anandamide transport, as revealed by selective inhibition. Science. 277, 1094–1097.
- Berdyshev, E. V., Schmid, P. C., Krebsbach, R. J., Hillard, C. J., Huang, C., Chen, N., Dong, Z. & Schmid, H. H. O. (2001a). Cannabinoid–receptor-independent cell signalling by N-acylethanolamines. Biochemical Journal. 360, 67–75.
- Berdyshev, E. V., Schmid, P. C., Krebsbach, R. J. & Schmid, H. H. O. (2001b). Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB Journal. 15, 2171–2178.
- Bisogno, T., Melck, D., Bobrov, M. Y., Gretskaya, N. M., Bezuglov, V. V., De Petrocellis, L. & Di Marzo, V. (2000). N-acyldopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal. 351, 817–824.
- Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Earth, F., Calandra, B., Pecceu, F., Lupker, J., Maffrand, J. P., Le Fur, G. & Casellas, P. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. Journal of Biological Chemistry. 272, 22330–22339.
- Bouchard, J. F., Lépicier, P. & Lamontagne, D. (2003). Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sciences. 72, 1859–1870.
- Brown, S. M., Wager-Miller, J. & Mackie, K. (2002). Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochimica Biophysica Acta. 1576, 255–264.
- Bukoski, R. D., Bátkai, S., Járai, Z., Wang, Y., Offertaler, L., Jackson, W. F. & Kunos, G. (2002). CB1 receptor antagonist SR141716A inhibits Ca2+ -induced relaxation in CB1 receptor-deficient mice. Hypertension. 39, 251–257.
- Childers, S. R., Sexton, T. & Roy, M. B. (1994). Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochemical Pharmacology. 47, 711–715.
- Chun, J., Goetzl, E. J., Hla, T., Igarashi, Y., Lynch, K. R., Moolenaar, W., Pyne, S. & Tigyi, G. (2002). International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacological Reviews. 54, 265–269.
- Coutts, A. A., Brewster, N., Ingram, T., Razdan, R. K. & Pertwee, R. G. (2000). Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. British Journal of Pharmacology. 129, 645–652.
- Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A. & Gilula, N. B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384, 83–87.
- D'Ambra, T. E., Estep, K. G., Bell, M. R., Eissenstat, M. A., Josef, K. A., Ward, S. J., Haycock, D. A., Baizman, E. R., Casiano, F. M., Beglin, N. C., Chippari, S. M., Grego, J. D., Kullnig, R. K. & Daley, G. T. (1992). Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective (aminoalkyl)indole agonists of the cannabinoid receptor. Journal of Medicinal Chemistry. 35, 124–135.
- De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J. B., Finazzi-Agro, A. & Di Marzo, V. (2001). The activity of anandamide at vanilloid VRI receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. Journal of Biological Chemistry. 276, 12856–12863.
- Deutsch, D. G., Goligorsky, M. S., Schmid, P. C., Krebsbach, R. J., Schmid, H. H. O., Das, S. K., Dey, S. K., Arreaza, G., Thorup, C., Stefano, G. & Moore, L. C. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. Journal of Clinical Investigation. 100, 1538–1546.
- Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S. & Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 34, 605–613.
- Dewey, W. L. (1986). Cannabinoid pharmacology. Pharmacological Reviews. 38, 151–178.
- Di Marzo, V., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A. & Martin, B. R. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1 non-CB2 receptor-mediated actions of anandamide in mouse brain. Journal of Neurochemistry. 57, 2434–2444.
- Di Marzo, V., Bisogno, T., De Petrocellis, L., Melck, D., Orlando, P., Wagner, J. A. & Kunos, G. (1999). Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. European Journal of Biochemistry. 264, 258–267.
- Di Marzo, V., Bisogno, T., Sugiura, T., Melck, D. & De Petrocellis, L. (1998a). The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophillike cells: connections with anandamide. Biochemical Journal. 331, 15–19.
- Di Marzo, V., De Petrocellis, L., Sepe, N. & Buono, A. (1996). Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochemical Journal. 316, 977–984.
- Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C. & Piomelli, D. (1994). Formation and in-activation of endogenous cannabinoid anandamide in central neurons. Nature. 372, 686–691.
- Di Marzo, V., Melck, D., Bisogno, T. & De Petrocellis, L. (1998b). Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in Neuroscience. 21, 521–528.
- Edgemond, W. S., Hillard, C. J., Falck, J. R., Kearn, C. S. & Campbell, W. B. (1998). Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Molecular Pharmacology. 54, 180–188.
- Ellis, E. F., Moore, S. F. & Willoughby, K. A. (1995). Anandamide and Δ9-tetrahydrocannabinol dilation of cerebral arteries is blocked by indomethacin. American Journal of Physiology. 269, H1859–H1864.
- Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D. & Leon, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences U.S.A.. 92, 3376–3380.
- Feigenbaum, J. J., Bergmann, F., Richmond, S. A., Mechoulam, R., Nadler, V., Kloog, Y. & Sokolovsky, M. (1989). Nonpsychotropic cannabinoid acts as a functional N-methyl-d-aspartate receptor blocker. Proceedings of the National Academy of Sciences U.S.A.. 86, 9584–9587.
- Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L. & Mitchell, R. L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Molecular Pharmacology. 48, 443–450.
- Ford, W. R., Honan, S. A., White, R. & Hiley, C. R. (2002). Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. British Journal of Pharmacology. 135, 1191–1198.
- Franco-Cereceda, A., Saria, A. & Lundberg, J. M. (1989). Differential release of calcitonin gene-related peptide and neuropeptide Y from the isolated heart by capsaicin, ischaemia, nicotine, bradykinin and ouabain. Acta Physiologica Scandinavica. 135, 173–187.
- Fukushima, N., Ishii, I., Contos, J. J. A., Weiner, J. A. & Chun, J. (2001). Lysophospholipid receptors. Annual Reviews of Pharmacology and Toxicology. 41, 507–534.
- Fulton, D. & Quilley, J. (1998). Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide-independent coronary vasodilator effect of bradykinin in the rat. Journal of Pharmacology and Experimental Therapeutics. 286, 1146–1151.
- Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G. & Casellas, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry. 232, 54–61.
- Galve-Roperh, I., Sánchez, C., Córtes, M. L., Del Pulgar, T. G., Izquierdo, M. & Guzmán, M. (2000). Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine. 6, 313–319.
- Gaoni, Y. & Mechoulam, R. (1964). Isolation, structure and partial synthesis of an active constituent of haschish. Journal of the American Chemical Society. 86, 1646–1648.
- Gebremedhin, D., Lange, A. R., Campbell, W. B., Hillard, C. J. & Harder, D. R. (1999). Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. American Journal of Physiology. 276, H2085–H2093.
- Gérard, C. M., Mollereau, C., Vassart, G. & Parmentier, M. (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal. 279, 129–134.
- Gifford, A. N., Tang, Y., Gatley, S. J., Volkow, N. D., Lan, R. & Makriyannis, A. (1997). Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neuroscience Letters. 238, 84–86.
- Gill, E. W. (1976). The effects of cannabinoids and other CNS depressants on cell membrane models. Annals of the New York Academy of Sciences. 281, 151–161.
- Glass, M. & Felder, C. C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. Journal of Neuroscience. 17, 5327–5333.
- Gómez del Pulgar, T., Velasco, G. & Guzmán, M. (2000). The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochemical Journal. 347, 369–373.
- Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D. & Hipkin, R. W. (2000). Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Molecular Pharmacology. 57, 1045–1050.
- Graham, J. D. P. & Li, D. M. F. (1973). Cardiovascular and respiratory effects of cannabis in the cat and rat. British Journal of Pharmacology. 49, 1–10.
- Guzmán, M., Galve-Roperh, I. & Sánchez, C. (2001). Ceramide, a new second messenger of cannabinoid action. Trends in Pharmacological Sciences. 22, 19–22.
- Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I. & Mechoulam, R. (2001). 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences U.S.A.. 98, 3662–3665.
- Hardman, H. F., Domino, E. F. & Seevers, M. H. (1971). General pharmacological actions of some synthetic tetrahydrocannabinol derivatives. Pharmacological Reviews. 23, 295–315.
- Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., De Costa, B. R. & Rice, K. C. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences U.S.A.. 87, 1932–1936.
- Hillard, C.J. (2000). Endocannabinoids and vascular function. Journal of Pharmacology and Experimental Therapeutics. 294, 27–32.
- Hillard, C.J., Manna, S., Greenberg, M.J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G. & Campbell, W. B. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). Journal of Pharmacology and Experimental Therapeutics. 289, 1427–1433.
- Ho, B. Y., Stadnicka, A., Prather, P. L., Buckley, A. R., Current, L. L., Bosnjak, Z. J. & Kwok, W. M. (2000). Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. Endocrinology. 141, 1675–1685.
- Howlett, A. C. & Fleming, R. M. (1984). Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Molecular Pharmacology. 26, 532–538.
- Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R. & Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews. 54, 161–202.
- Howlett, A. C., Qualy, J. M. & Khachatrian, L. L. (1986). Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Molecular Pharmacology. 29, 307–313.
- Huang, S. M., Bisogno, T., Petros, T.J., Chang, S. Y., Zavitsanos, P. A., Zipkin, R. E., Sivakumar, R., Coop, A., Maeda, D. Y., De Petrocellis, L., Burstein, S., Di Marzo, V. & Walker, J. M. (2001). Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. Journal of Biological Chemistry. 276, 42639–42644.
- Ishac, E. J., Jiang, L., Lake, K. D., Varga, K., Abood, M. E. & Kunos, G. (1996). Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. British Journal of Pharmacology. 118, 2023–2028.
- Ishioka, N. & Bukoski, R. D. (1999). A role for N-arachidonylethanolamine (anandamide) as the mediator of sensory nerve-dependent Ca2+ -induced relaxation. Journal of Pharmacology and Experimental Therapeutics. 289, 245–250.
- Járai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., Razden, R. K., Zimmer, A. & Kunos, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences U.S.A.. 96, 14136–14141.
- Jonassen, A. K., Sack, M. N., Mjos, O. D. & Yellon, D. M. (2001). Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circulation Research. 89, 1191–1198.
- Jones, R. T. (2002). Cardiovascular effects of marijuana. Journal of Clinical Pharmacology. 42 (Suppl. 11), 58S–63S.
- Joyeux, M., Arnaud, C., Godin-Ribuot, D., Demenge, P., Lamontagne, D. & Ribuot, C. (2002). Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovascular Research. 55, 619–625.
- Kallner, G., Owall, A. & Franco-Cereceda, A. (1999). Myocardial outflow of calcitonin gene-related peptide in relation to metabolic stress during coronary artery bypass grafting without cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery. 117, 447–453.
- Kanakis, C., Pouget, J. M. & Rosen, K. M. (1976). The effects of Δ9–THC (cannabis) on cardiac performance with or without beta blockade. Circulation. 53, 703–709.
- Knoller, N., Levi, L., Shoshan, I., Reichenthal, E., Razon, N., Rappaport, Z. H. & Biegon, A. (2002). Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Critical Care Medicine. 30, 548–554.
- Lagneux, C. & Lamontagne, D. (2001). Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. British Journal of Pharmacology. 132, 793–796.
- Lake, K. D., Compton, D. R., Varga, K., Martin, B. R. & Kunos, G. (1997). Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors Journal of Pharmacology and Experimental Therapeutics 281, 1030–1037.
- Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J. F., Beslot, F., Bohme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., Vassart, G., Fratta, W. & Parmentier, M. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 283, 401–404.
- Liu, J., Gao, B., Mirshahi, F., Sanyal, A.J., Khanolkar, A. D., Makriyannis, A. & Kunos, G. (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochemical Journal. 346, 835–840.
- Maccarrone, M., Bari, M., Battista, N. & Finazzi-Agro, A. (2002). Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood. 100, 4040–4048.
- Maccarrone, M., Lorenzon, T., Bari, M., Melino, G. & Finazzi-Agro, A. (2000). Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. Journal of Biological Chemistry. 275, 31938–31945.
- Martin, B. R., Compton, D. R., Thomas, B. F., Prescott, W. R., Little, P. J., Razdan, R. K., Johnson, M. R., Melvin, L. S., Mechoulam, R. & Ward, S. J. (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacology Biochemistry Behavior. 40, 471–478.
- Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346, 561–564.
- Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Pertwee, R. G., Griffin, G., Bayewitch, M., Barg, J. & Vogel, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology. 50, 83–90.
- Mechoulam, R., Fride, E. & Di Marzo, B. (1998). Endocannabinoids. European Journal of Pharmacology. 359, 1–18.
- Mittleman, M. A., Lewis, R. A., Maclure, M., Sherwood, J. B. & Muller, J. E. (2001). Triggering myocardial infarction by marijuana. Circulation. 103, 2805–2809.
- Moesgaard, B., Petersen, G., Mortensen, S. A. & Hansen, H. S. (2002). Substantial species differences in relation to formation and degradation of N-acyl-ethanolamine phospholipids in heart tissue: an enzyme activity study. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology. 131, 475–482.
- Molderings, G. J., Bönisch, H., Hammermann, R., Göthert, M. & Brüss, M. (2002). Noradrenaline release-inhibiting receptors on PC12 cells devoid of α2- and CB1 receptors: similarities to presynaptic imidazoline and edg receptors. Neurochemistry International. 40, 157–167.
- Mombouli, J. V., Schaeffer, G., Holzmann, S., Kostner, G. M. & Graier, W. F. (1999). Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. British Journal of Pharmacology. 126, 1593–1600.
- Mu, J., Zhuang, S. Y., Kirby, M. T., Hampson, R. E. & Deadwyler, S. A. (1999). Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. Journal of Pharmacology and Experimental Therapeutics. 291, 893–902.
- Munro, S., Thomas, K. L. & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365, 61–65.
- Niederhoffer, N. & Szabo, B. (1999a). Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. British Journal of Pharmacology. 126, 457–466.
- Niederhoffer, N. & Szabo, B. (1999b). Involvement of CB1 cannabinoid receptors in the EDHF-dependent vasorelaxation in rabbits. British Journal of Pharmacology. 126, 1383–1386.
- Offertáler, L., Mo, F.-M., Bátkai, S., Liu, J., Begg, M., Razdan, R. K., Martin, B. R., Bukoski, R. D. & Kunos, G. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular Pharmacology. 63, 699–705.
- Pacheco, M. A., Ward, S. J. & Guilders, S. R. (1993). Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Research. 603, 102–110.
- Pertwee, R. G. (2000). Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opinion on Investigational Drugs. 9, 1553–1571.
- Pertwee, R. G., Stevenson, L. A., Elrick, D. B., Mechoulam, R. & Corbett, A. D. (1992). Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. British Journal of Pharmacology. 105, 980–984.
- Pestonjamasp, V. K. & Burstein, S. H. (1998). Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochimica Biophysica Acta. 1394, 249–260.
- Plane, F., Holland, M., Waldron, G. J., Garland, C. J. & Boyle, J. P. (1997). Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. British Journal of Pharmacology. 121, 1509–1511.
- Porter, A. C., Sauer, J. M., Knierman, M. D., Becker, G. W., Berna, M.J., Bao, J., Nomikos, G. G., Carter, P., Bymaster, F. P., Leese, A. B. & Felder, C. C. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Journal of Pharmacology and Experimental Therapeutics. 301, 1020–1024.
- Pratt, P. F., Hillard, C. J., Edgemond, W. S. & Campbell, W. B. (1998). N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. American Journal of Physiology. 274, H375–H381.
- Ralevic, V. & Kendall, D. A. (2001). Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. European Journal of Pharmacology. 418, 117–125.
- Ralevic, V. & Kendall, D. A. (2002). Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. European Journal of Pharmacology. 444, 171–181.
- Ralevic, V., Kendall, D. A., Randall, M. D. & Smart, D. (2002). Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sciences. 71, 2577–2594.
- Randall, M. D. & Kendall, D. A. (1997). Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. European Journal of Pharmacology. 335, 205–209.
- Randall, M. D., Alexander, S. P. H., Bennett, T., Boyd, E. A., Fry, J. R., Gardiner, S. M., Kemp, P. A., Mcculloch, A. I. & Kendall, D. A. (1996). An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochemical and Biophysical Research Communications. 229, 114–120.
- Randall, M. D., Harris, D., Kendall, D. A. & Ralevic, V. (2002). Cardiovascular effects of cannabinoids. Pharmacology and Therapeutics. 95, 191–202.
- Rhee, M. H., Bayewitch, M., Avidor-Reiss, T., Levy, R. & Vogel, Z. (1998). Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. Journal of Neurochemistry. 71, 1525–1534.
- Rinaldi-Carmona, M., Barth, F., Heauleme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrara, P., Soubrie, P., Breliere, J. C. & Le Fur, G. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters. 350, 240–244.
- Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J. M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Breliere, J. C. & Le Fur, G. L. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics. 284, 644–650.
- Rinaldi-Carmona, M., Calandra, B., Shire, D., Bouaboula, M., Oustric, D., Barth, F., Casellas, P., Ferrara, P. & Le Fur, G. (1996). Characterization of two cloned human CB1 isoforms. Journal of Pharmacology and Experimental Therapeutics. 278, 871–878.
- Ross, R. A., Brockie, H. C., Stevenson, L. A., Murphy, V. L., Templeton, F., Makriyannis, A. & Pertwee, R. G. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. British Journal of Pharmacology. 126, 665–672.
- Schmid, P. C., Krebsbach, R. J., Perry, S. R., Dettmer, T. M., Maasson, J. L. & Schmid, H. H. O. (1995). Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Letters. 375, 117–120.
- Schmid, P. C., Schwartz, K. D., Smith, C. N., Krebsbach, R. J., Berdyshev, E. V. & Schmid, H. H. O. (2000). A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanol-amines and 2-monoacylglycerols. Chemistry and Physics of Lipids. 104, 185–191.
- Schmid, H. H. O., Schmid, P. C. & Natarajan, V. (1990). N-acylated glycerophospholipids and their derivatives. Progress in Lipid Research. 29, 1–43.
- Shire, D., Carillon, C., Kaghad, M., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., Caput, D. & Ferrara, P. (1995). An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. Journal of Biological Chemistry. 270, 3726–3731.
- Shohami, E., Gallily, R., Mechoulam, R., Bass, R. & Ben-Hur, T. (1997). Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. Journal of Neuroimmunology. 72, 169–177.
- Showalter, V. M., Compton, D. R., Martin, B. R. & Abood, M. E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. Journal of Pharmacology and Experimental Therapeutics. 278, 989–999.
- Sidney, S. (2002). Cardiovascular consequences of marijuana use. Journal of Clinical Pharmacology. 42 (Suppl. 11), 64S–70S.
- Slipetz, D. M., O'Neill, G. P., Favreau, L., Dufresne, C., Gallant, M., Gareau, Y., Guay, D., Labelle, M. & Metters, K. M. (1995). Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Molecular Pharmacology. 48, 352–361.
- Stella, N., Schweitzer, P. & Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388, 773–778.
- Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H. & Waku, K. (1990). Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. Journal of Biological Chemistry. 275, 605–612.
- Sugiura, T., Kodaka, T., Nakane, S., Kishimoto, S., Kondo, S. & Waku, K. (1998). Detection of an endogenous cannabiminietic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator Biochemical and Biophysical Research Communications 243, 838–843.
- Varga, K., Lake, K. D., Huangfu, D., Guyenet, P. G. & Kunos, G. (1996). Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension. 28, 682–686.
- Varga, K., Lake, K. D., Martin, B. R. & Kunos, G. (1995). Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. European Journal of Pharmacology. 278, 279–283.
- Varga, K., Wagner, J. A., Bridgen, T. D. & Kunos, G. (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB Journal. 12, 1035–1044.
- Vogel, Z., Barg, J., Levy, R., Saya, D., Heldman, E. & Mechoulam, R. (1993). Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. Journal of Neurochemistry. 61, 352–355.
- Wagner, J. A., Varga, K. & Kunos, G. (1998). Cardiovascular actions of cannabinoids and their generation during shock. Journal of Molecular Medicine. 76, 824–836.
- Wagner, J. A., Hu, K., Bauersachs, J., Karcher, J., Wiesler, M., Goparaju, S. K., Kunos, G. & Ertl, G. (2001). Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. Journal of the American College of Cardiologists. 38, 2048–2054.
- Wagner, J. A., Hu, K., Karcher, J., Bauersachs, J., Shäfer, A., Laser, M., Han, H. & Ertl, G. (2003). CB1 cannabinoid receptor antagonism promoted remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. British Journal of Pharmacology. 134, 1251–1258.
- Wagner, J. A., Varga, K., Ellis, E. F, Rzigalinski, B. A., Martin, B. R. & Kunos, G. (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 390, 518–521.
- Wagner, J. A., Varga, K., Járai, Z. & Kunos, G. (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension. 33, 429–434.
- Wang, Y., Liu, Y., Ito, Y., Hashiguchi, T., Kitajima, I., Yamakuchi, M., Shimizu, H., Matsuo, S., Imaizumi, H. & Maruyama, I. (2001). Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Analytical Biochemistry. 294, 73–82.
- Ward, S.J., Mastriani, D., Casiano, F. & Arnold, R. (1990). Pravadoline: profile in isolated tissue preparations. Journal of Pharmacology and Experimental Therapeutics. 255, 1230–1239.
- White, R. & Hiley, C. R. (1997). A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. British Journal of Pharmacology. 122, 1573–1584.
- White, R. & Hiley, C. R. (1998a). The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. British Journal of Pharmacology. 125, 533–541.
- White, R. & Hiley, C. R. (1998b). The actions of the cannabinoid receptor antagonist, SR141716A, in the rat isolated mesenteric artery. British Journal of Pharmacology. 125, 689–696.
- White, R., Ho, W.-S. V., Bottrill, F. E., Ford, W. R. & Hiley, C. R. (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. British Journal of Pharmacology. 134, 921–929.
- Yamaguchi, F., Tokuda, M., Hatase, O. & Brenners, S. (1996). Molecular cloning of the novel human G protein-coupled receptor (GPCR) gene mapped on chromosome 9. Biochemical and Biophysical Research Communications. 227, 608–614.
- Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sorgard, M., Di Marzo, V., Julius, D. & Hogestatt, E. D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400, 452–457.